Blood ratios may predict lung failure in burned kids
NCT ID NCT07414056
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether two simple blood test results—the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio—can help predict which children with severe burns will develop acute respiratory distress syndrome (ARDS), a serious lung condition. Researchers will follow 60 children aged 1-12 with burns covering 20-40% of their body. The goal is to find early warning signs so doctors can act faster.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could give doctors a simple, early way to predict which burned children are at risk of severe lung failure, allowing faster, more targeted care.
- What could go wrong
- This is a small, early study with only 60 children. The blood ratios may not be accurate enough to reliably predict ARDS in all cases, and results may not apply to other burn types or ages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
A prospective observational cohort study will be performed in our burn ICU at Ain Shams University Hospitals. Ethical clearance will be taken from the institutional ethics committee. Written informed consent will be obtained from the patients/authorized representatives of the patients. All eligible pediatric patients with severe burns will be enrolled within 24 hours of admission after obtaining informed consent. Minimum sample needed for statistical significance was calculated a priori and found to be (60). After consent, Patients' characteristics (age, sex, etc….), clinical parameters (TBSA, Abbreviated Burn Severity Index \[ABSI\], presence of inhalational injury), and comorbidities will be recorded. Patients will be evaluated on days 0,1, 3, 5, 7 of admission for diagnosis of ARDS. ARDS will be determined using the pediatric ARDS criteria from the Pediatric Acute Lung Injury Consensus Conference .
- Ages
-
1 year to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 1-12 years. * Patients presenting within 24 hours of burn injury. * Patients presenting with severe burns 20-40% of total body surface area (TBSA). * Thermal burns or scalds. * Both sexes. Exclusion Criteria: * Patient refusal to participate in the trial. * Age \<1 \& \>12 years. * Delayed admission \>24h post-injury. * Patients presenting with burns \<20% or \>40% of TBSA. * Non-thermal burns. * Associated medical comorbidities: Chronic liver or kidney diseases, anemia. * Preexisting chronic lung disease (e.g., cystic fibrosis, severe bronchopulmonary dysplasia). * Inflammatory conditions (e.g., inflammatory bowel disease). * Immunocompromised individuals, autoimmune diseases, those undergoing treatment with immunosuppressants, corticosteroids, cytotoxic chemotherapy. * Known malignancies, hematologic malignancy or conditions altering WBC/platelets significantly. * Previous malnutrition. * Immunosuppressive therapy prior to admission (e.g., chronic steroids).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome (ARDS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ain Shams University
RECRUITINGCairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Real-Time lung imaging Fine-Tune ventilator care for ARDS?
- Can tailored breathing support and early muscle relaxants boost survival in ARDS?
- Immune clues may unlock better ECMO care for lung failure patients
- New study aims to Fine-Tune ventilator strategies for ARDS patients
- Can the right dose and timing of steroids save more lives in ARDS?
- New inflatable cushion could revolutionize ICU patient repositioning